Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/scitranslmed.abf4530 | DOI Listing |
Publication Analysis
Top Keywords
clinical trials
8
trials human
8
response comment
4
comment "evaluating
4
"evaluating cardiovascular
4
cardiovascular safety
4
safety sclerostin
4
sclerostin inhibition
4
inhibition evidence
4
evidence meta-analysis
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!